3989 E 170 N
Rigby, ID 83442
Phone 208-344-4476

Our Focus

The Idaho Chapter of the National Hemophilia Foundation provides education, support, awareness, and advocacy for our bleeding disorder community. We are the leading resource for those affected by bleeding disorders in the state of Idaho. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

News Articles

On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor replacement therapies. The lack of access to residential addiction treatment facilities, can have very serious, even fatal outcomes for bleeding disorder (BD) patients in acute need of help with their addiction.

Envisioning a united community that will make a positive difference in the lives of individuals affected by a bleeding disorder.

Education
Advocation
Inclusions
Development

3989 E 170 N
Rigby, ID 83442
Phone 208-344-4476

© Idaho Chapter of the National Hemophilia Foundation 2022

Crafted by Firespring